TAM April 2019 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
April 2019, Volume 27, Issue 1
- CME Credit Available: 12.0 AMA PRA Category 1 Credits™
- Release Date: May 10, 2019
- Expiration Date: May 10, 2020
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
On completion of this activity, the learner will be able to describe the important new data presented at the 2019 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of:
- Basic science understanding of HIV
- Preexposure prophylaxis and other HIV prevention efforts
- Neurologic complications of HIV infection
- Coinfections and other complications of HIV infection
- Viral hepatitis
- Antiretroviral therapy for HIV prevention and management
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and HCV infections.
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and HCV infections.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 12.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from May 10, 2019, to May 10, 2020. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with commercial interests, enabling the audience members to form their own judgments about such associations.
Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Financial relationship information about authors is included here and at the end of each article; information on the TAM Editorial Board may be found here.
Dr Ances has no relevant financial affiliations to disclose.
Dr Buchbinder has participated in research trials that received provision of medicines from Gilead Sciences, Inc.
Dr Havlir has participated in research trials that received provision of medicines from Gilead Sciences, Inc.
Dr Jones has no relevant financial affiliations to disclose.
Dr Letendre has had travel paid for by ViiV Healthcare. Dr Currier has received grant support awarded to her institution from Theratechnologies.
Dr Liu has participated in research trials that received provision of medicines from Gilead Sciences, Inc.
Dr Luetkemeyer has received grant support awarded to her institution from AbbVie, Gilead Sciences, Inc, Merck & Co, Inc, Proteus, and ViiV Healthcare.
Dr Stevenson has no relevant financial affiliations to disclose.
Dr Taylor has no relevant financial affiliations to disclose.
Dr Tieu has received grant support awarded to her institution from Gilead Sciences, Inc.
Dr Wilkin has served as an advisor or consultant to GlaxoSmithKline/ViiV Healthcare and has received grant support awarded to his institution from GlaxoSmithKline/ViiV Healthcare. His spouse owns stock in Johnson & Johnson.
Dr Wyles has received grant support awarded to his institution from Gilead Sciences, Inc.
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/09/19)
The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2019 Improving the Management of HIV Disease® CME program:
Gilead Sciences, Inc
Merck & Co, Inc
Additional support provided by Janssen Therapeutics.
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 425 California St, Ste 1450, San Francisco, CA 94104-2120
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.